Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening period through  days after the last dose of protocol therapy
Subject is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study treatment.
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study drug.
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study starting with the screening visit through  days after the last dose of pembrolizumab or through  days after the last dose of paclitaxel, docetaxel or irinotecan
Pregnant or breastfeeding or expecting to conceive or father children from the Screening Visit (Visit ) through  days after last dose of study drug
Is pregnant or breastfeeding or expecting to conceive or father children starting with the screening visit through  days after the last dose of study therapy
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study drug or within the  day period after the last dose of study drug.
Is pregnant or breast feeding or expecting to conceive or father starting from the first dose of study medication, throughout the study period, and for up to  days after the last dose of study medication
Is pregnant or breast-feeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study treatment.
Patients may not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, from registration through  days after the last dose of trial treatment
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
Pregnant, breastfeeding, or expecting to conceive children within projected duration of study
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study medication
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through  days after the last dose of study medication
Is pregnant or breastfeeding, or expecting to conceive or father children while on study drug and for the required duration of contraception after the last dose of study drug.
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
If female, is pregnant, breastfeeding, or expecting to conceive starting with the screening visit through  days after the last dose of study drug.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the Screening visit through  days after the last dose of study treatment.
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting from Screening through to  days after the last dose of study treatment.
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Subjects must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the final dose of study medication
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting from the time of consent through  days after the last dose of trial treatment
Pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial through  days after the last dose of study treatment
Patients who are pregnant or breastfeeding, or expecting to conceive within the projected duration of the study; lactating patients will be excluded from this study
Subject is pregnant or breastfeeding, or expecting to conceive or father a child within the projected duration of the trial participation (from  weeks prior to the first dose of study treatment, while participating on the study and through  days after the last dose of trial treatment)
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including  days following the last dose of study treatment; or
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
Pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of pembrolizumab and up to  days after the last dose of chemotherapeutic agents.
Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of SOC or  days after the last dose of pembrolizumab
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the first dose of study drug through  days or longer based on local regulation after the last dose of study drug.
Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving study treatment and for  days after the last dose of study treatment
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through  days after the last dose of study drug.
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of study medication
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of pembrolizumab or  days after the last dose of chemotherapy treatment.
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study treatment
Pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study drug.
Is pregnant or breastfeeding, or expecting to conceive or father children prior to  days after the last dose of study medication or through  days after last dose of chemotherapeutic agents.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study drug.
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through - days after the last dose of study drug according to local standard of care
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through  days after the last dose of study drug
Pregnant or breastfeeding, or expecting to conceive or father children during the study and through  days after last dose of pembrolizumab or  days after last dose of SOC chemotherapy
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial from screening through  days after the last dose of study drug
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through  days after last dose of pembrolizumab or  days after last dose of docetaxel
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study medication
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study medication.
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of pembrolizumab or through  days after the last dose of paclitaxel.
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of study medication
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of study medication
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of pembrolizumab or  days after the last dose of paclitaxel, docetaxel, or vinflunine
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after the last dose of study medication and up to  days after last dose of cisplatin
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study starting with the screening visit through  days after the last dose of study treatment through and up to  days after last dose of chemotherapeutic agents
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through  months after the last dose of study treatment for participants who have received cyclophosphamide, and for  months after the last dose of study treatment for participants who have not.
Patient is pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, because of the potential for serious adverse reactions in nursing infants from vorinostat, breast feeding must be discontinued for the duration of therapy with vorinostat
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study drug or for  days after the last dose of study drug.
Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving study treatment and for  months after the last dose of study treatment
Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving study treatment and for  months after the last dose of study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK- (pembrolizumab); patients are excluded from this study if pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days after the last dose of trial treatment
Is pregnant or breast feeding or expecting to conceive or father children throughout the study period and for up to  days after the last dose of study therapy
Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through  days after the last dose of study drug
Female participants who are pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through days after the last dose of chemotherapy or through  days after the last dose of pembrolizumab, whichever is greater.
Male participants who are expecting to father children within the projected duration of the study, starting with the screening visit through  days after the last dose of chemotherapy.
Pregnant or nursing women or subjects expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days after last dose of study drug.
Subject is pregnant or breast-feeding, or expecting to conceive or father children within the duration of the trial
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through  days (or longer as specified by local institutional guidelines) after the last dose of study drug.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through  days (for participants receiving pembrolizumab) or  days (for participants receiving BV) after the last dose of study drug.
